UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

SIMULATIONS PLUS (WKN: 924294) SLP

Seite 1 von 1
neuester Beitrag: 14.11.19 07:29
eröffnet am: 18.05.16 19:01 von: Tamakoschy Anzahl Beiträge: 17
neuester Beitrag: 14.11.19 07:29 von: Tamakoschy Leser gesamt: 4493
davon Heute: 3
bewertet mit 0 Sternen

2046 Postings, 3599 Tage TamakoschySIMULATIONS PLUS (WKN: 924294) SLP

 
  
    
18.05.16 19:01
Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemical, cosmetic, herbicide, and food ingredient industries today. Our software allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research & development costs and helping clients make better projects decisions... sooner.

Founded in 1996, Simulations Plus employs over 30 employees (22 with Ph.D. or M.S. degrees) and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP).  Our headquarters are based in Lancaster, California, with trusted distributors handling sales and scientific support in Asian territories. All of the top 20 pharmaceutical companies, plus numerous mid- and small-sized companies and all major regulatory agencies, license our software.

Consulting services:   our team of highly-skilled scientists is available to assist with your discovery and development activities on a project-by-project basis. With the acquisition of Cognigen Corporation in 2014, we are now able to offer expanded pharmacodynamic modeling services, NONMEM analysis, and regulatory report writing assistance. The ultimate goal of the merger is to develop tools and systems which bridge PBPK modeling with clinical trial data analysis.

Our expertise, combined with our best-in-class software, provides you with modeling and simulation analyses, from discovery through late-stage clinical development, which can greatly improve your decision-making process.

Training workshops & User Groups:  we offer hands-on introductory and advanced training workshops to learn our software throughout the year. Workshops are held in the United States, Europe, and Asia. We also host an annual Software User Forum each year convened to enhance product knowledge and strengthen communications between Simulations Plus and its worldwide community of users. Additionally, in 2013 scientists from 17 companies formed the GastroPlus? User Group, which has an online community of 460 members that discuss best practices, provide feedback on new features, and promote the use of PBPK modeling & simulation across various industries.
- See more at: http://www.simulations-plus.com/Aboutus.aspx#sthash.cx9f8iSs.dpuf
.

http://www.simulations-plus.com/PressRelease.aspx

Fundamental:
.
http://de.4-traders.com/SIMULATIONS-PLUS-INC-771786/fundamentals/
.
http://financials.morningstar.com/...ment/is.html?t=SLP&ops=clear
.
http://seekingalpha.com/symbol/SLP  

2046 Postings, 3599 Tage TamakoschyQ4 und Jahreszahlen

 
  
    
12.11.16 13:29

2046 Postings, 3599 Tage TamakoschyKurs nach Q1 17 Zahlen über 5 % im plus

 
  
    
10.01.17 16:55
Simulations Plus Reports First Quarter FY2017 Financial Results
Consolidated net earnings up 23.1% on 12% revenue increase

January 09, 2017
 

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2017, the period ended November 30, 2016 (1QFY17).
1QFY17 highlights compared with 1QFY16:
Net revenues increased 12.0%, or $579,000, to a new first quarter record $5.42 million vs. $4.84 million
Gross profit increased 8.7% to $4.08 million from $3.76 million
SG&A was $1.86 million, an increase of $187,000 or 11.2%, from $1.68 million
SG&A as a percentage of revenues decreased slightly from 34.6% to 34.4%
Income before taxes increased $250,000 or 14.6%, to $1.97 million from $1.72 million
Net income increased $255,000 or 23.1%, to $1.36 million from $1.11 million
Diluted earnings per share increased 22% or $0.014, to $0.078 from $0.064 per share



https://www.irdirect.net/prviewer/release/id/2276824


 

2046 Postings, 3599 Tage TamakoschyQ2 17 es geht wieder abwärts

 
  
    
11.04.17 21:16
https://seekingalpha.com/pr/...econd-quarter-fy2017-financial-results

EPS of $0.07 misses by $-0.01 | Revenue of $ (- 100.0% Y/Y) misses by $-5.54M

Record second quarter as revenues grow 10.5%, 6MoFY17 net income up 13.6%
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2017, the period ended February 28, 2017 (2QFY17).  

2046 Postings, 3599 Tage TamakoschyFourth-Quarter-and-Fiscal-Year-2017

 
  
    
14.10.17 12:19

2046 Postings, 3599 Tage TamakoschyFY2017 and Fourth Quarter FY2017 Financial Results

 
  
    
15.11.17 17:13
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 20.9%;
Earnings per share of $0.33, up 14.9% over prior year

http://www.4-traders.com/...uarter-FY2017-Financial-Results-25506597/  

2046 Postings, 3599 Tage Tamakoschyannual government license for its flagship QSP

 
  
    
10.05.18 08:37

2046 Postings, 3599 Tage TamakoschyQ4

 
  
    
14.11.19 07:29
https://www.marketscreener.com/...-FY2019-Financial-Results-29574276/

Full Year FY19 highlights compared with Full Year FY18:
Revenues were $34.0 million, up 14.5% over $29.7 million in FY18
Gross profit was up 15.1%, or $3.3 million, to $24.9 million, from $21.7 million in FY18
SG&A was $11.8 million, an increase of $2.2 million, or 23.1%, over $9.6 million
Total R&D expenditures were $4.3 million, an increase of $363,000, or 9.2% over $3.9 million
For FY19, $1.8 million was capitalized and $2.5 million was expensed
For FY18, $2.1 million was capitalized and $1.8 million was expensed
Income before taxes increased 4.1% to $10.6 million, an increase of $418,000 over $10.1 million
Net income decreased 3.9% to $8.6 million, a decrease of $351,000 from $8.9 million; FY18 included the one-time second-quarter tax benefit of $1.5 million
Diluted earnings per share decreased 5.0% to $0.48 from $0.50. In FY18, the major change in diluted earnings per share came from the $1.5 million tax adjustment that accounted for an $0.08 increase in diluted earnings per share
Cash was $11.4 million, an increase of $2.0 million, or 21.6%, from $9.4 million at the end of FY18.
4QFY19 highlights compared with 4QFY18:
Revenues increased 20.0% to $8.0 million, an increase of $1.3 million over $6.7 million
Gross profit was up 25.6% to $5.7 million, an increase of $1.2 million over $4.6 million
SG&A was $3.2 million, an increase of 42.6%, or $951,000, over $2.2 million
Total R&D expenditures were $1.0 million, an increase of $89,000, or 9.4%, over $951,000
For 4QFY19, $437,000 was capitalized and $603,000 was expensed
For 4QFY18, $514,000 was capitalized and $437,000 was expensed
Income before taxes increased 7.9% to $2.0 million, an increase of $146,000 over $1.8 million
Net income increased 53.9% to $2.1 million, an increase of $721,000 over $1.3 million
Earnings per fully diluted share increased $0.03 to $0.11 from $0.08  

   Antwort einfügen - nach oben

  3 Nutzer wurden vom Verfasser von der Diskussion ausgeschlossen: Ciriaco, phre22, hormiga